{"id":14048,"date":"2026-02-27T20:56:33","date_gmt":"2026-02-27T16:56:33","guid":{"rendered":"https:\/\/medscriptum.org\/?p=14048"},"modified":"2026-02-27T20:56:59","modified_gmt":"2026-02-27T16:56:59","slug":"how-regenerative-medicine-is-transforming-the-management-of-severe-diseases-in-japan-by-2026","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/how-regenerative-medicine-is-transforming-the-management-of-severe-diseases-in-japan-by-2026\/","title":{"rendered":"How Regenerative Medicine Is Transforming the Management of Severe Diseases in Japan by 2026"},"content":{"rendered":"

Regenerative medicine is based on the use of those biological mechanisms that allow the organism to regrow and restore damaged tissues. For decades, this field primarily existed in laboratory experiments and theoretical research, although by 2026, technology has reached the stage where its practical use is already a reality.<\/p>\n

In this turning process, Japan plays a key role. The country’s Ministry of Health has issued conditional permission for two new products derived from iPS (induced pluripotent stem) cells, which is an important step toward the commercialization of this field. The cells created by Sumitomo Pharma serve the treatment of Parkinson’s disease, while Cuorips’ technology is directed against heart failure (ischemic cardiomyopathy).<\/p>\n

On the basis of applications presented in 2025, experts recommended the production and sale of these preparations, although they established a seven-year observation period to finally confirm their safety.<\/p>\n

Despite the fact that more than 60 iPS studies have been conducted in the world since 2006, until now not a single product had reached commercialization\u2014including in Japan, the homeland of iPS. This 2026 decision means that regenerative medicine is moving from laboratories directly into clinical practice.<\/p>\n

What is iPS?<\/b><\/h5>\n

Induced pluripotent stem (iPS) cells create a completely new possibility for the restoration of damaged tissues. Scientists take ordinary adult cells (for example, skin cells) and reprogram them through four key proteins (\u201cYamanaka factors\u201d – Oct4, Sox2, Klf4, and c-Myc). This process returns the cells to a state similar to stem cells, where they can divide indefinitely and transform into any tissue of the body.<\/p>\n

Unlike embryonic stem cells, iPS technology \u201cbypasses\u201d ethical problems because it uses adult cells, while versions tailored to the patient reduce the risks of their rejection by the organism.<\/p>\n

In laboratory conditions, these \u201cuniversal\u201d cells develop with a specific purpose. For example, for the treatment of Parkinson’s disease, they create from them those neurons that produce dopamine, and for the restoration of heart damage\u2014 \u201cbeating\u201d cardiomyocytes.<\/p>\n

\"\"
ScienceDircet<\/figcaption><\/figure>\n
Historical Development\u00a0<\/b><\/h5>\n

Japan’s scientific progress in the field of iPS cells began in 2006, when Shinya Yamanaka managed the successful generation of cells from mouse fibroblasts at Kyoto University, which was later followed by work on human cells. This epochal discovery won the Nobel Prize in 2012<\/a>, which determined the turning of the issue into a national priority and large-scale support from the state. The government of Japan divided the development plan into three sequential phases.<\/p>\n

The first phase (2003-2012) was devoted to the project of the realization of regenerative medicine. During this period, approximately 36.5 billion yen was spent on stem cell technologies, new therapies, and the creation of specialized banks. Yamanaka’s success opened the way to the next stage, which envisioned the further expansion of research bases.<\/p>\n

Within the framework of the second phase (2013-2022), Japan created a unified network of regenerative medicine research centers. The Center for iPS Cell Research and Application (CiRA<\/a>) at Kyoto University became the main epicenter of the process. The clinical-grade haplobank<\/a> of CiRA, which covers approximately 40% of the Japanese population, is considered the most important achievement of this period. Finally, twelve different projects moved to the stage of clinical trials.<\/p>\n

Today, the country is in the third phase of development (2023-2027), the main priority of which is the industrialization and acceleration of technologies. Several ministries are involved in the process, which oversee research, clinical supervision, and production.<\/p>\n

Regulatory Framework: The Two-Track System and Conditional Permissions<\/b><\/h5>\n

The secret of Japan’s success is the \u201ctwo-track system\u201d introduced in 2014, which sharply accelerated the development of regenerative medicine. The legislation<\/a> divides treatment methods according to risk: while iPS cells are subject to strict control, low-risk procedures maintain more freedom. This approach allows scientists to start primary research on humans much earlier than is possible in other countries.<\/p>\n

This process is further accelerated by the so-called \u201cconditional approval\u201d mechanism (CTL). If a preparation is safe and gives hope for effectiveness, it is granted a 7-year \u201ctrial term\u201d to enter the market. By 2025, five products had already benefited from this system, although this does not mean that the state is compromising: the recall of two preparations (Collategene and HeartSheet) confirms that if the real results do not justify expectations, the authorization is immediately revoked.<\/p>\n

Since 2007, 21 regenerative products have already been permitted in the country. Special attention is paid to the safety of iPS cells: the quality standards established in 2012 were supplemented in 2019 by strict mechanisms for the detection of tumor risks. Today, the regulatory body (PMDA<\/a>) places emphasis on \u201creal-world data\u201d (RWD), which means that the effectiveness of the treatment is checked even more accurately and transparently, not only laboratory-wise but on the basis of daily observation of patients.<\/p>\n

From Research to Patients: Stages of Development<\/b><\/h5>\n

The Japan Registry of Clinical Trials (jRCT<\/a>) today brings together many projects based on iPS cells. This process develops in three main ways: first\u2014academic research, which searches for ways of treating 14 different diseases in universities. Second\u2014large industrial projects, where biotechnological giants work on the mass production of these technologies. While the third direction is devoted to the discovery of new drugs, where they model diseases through iPS cells and test the effectiveness of potential medications.<\/p>\n

The world’s first iPS study<\/a> published in 2014, which concerned the degeneration of the retina of the eye, is considered the greatest success of the academic sphere. Since then, the area of research has expanded significantly and today already includes such difficult pathologies as Parkinson’s disease, heart failure, and since 2024 – type 1 diabetes mellitus as well.<\/p>\n

In the industrial sector, the project of the company Heartseed (HS-001<\/a>) is under special attention, which uses allogeneic cardiomyocytes to restore heart function. In parallel, iPS technology allows scientists to test new medications for the treatment of amyotrophic lateral sclerosis (ALS), Alzheimer’s, and other rare genetic disorders.<\/p>\n

\"\"
ScienceDirect<\/figcaption><\/figure>\n

To the list of products already approved today, the projects of Cuorips<\/a> and Sumitomo Pharma<\/a> are also being added. The applications presented in April and August of 2025 establish a new standard in this field. This means that iPS technology successfully passed a difficult technological path and is now already ready for large-scale medical consumption.<\/p>\n

Safety and Production Challenges<\/b><\/h5>\n

Despite the great potential, iPS technology is also connected with certain risks. One of the main challenges is the danger of tumor formation, which might be caused by those residual, incompletely transformed cells that continue unpredictable growth in the organism.<\/p>\n

To hedge these risks, the Ministry of Health of Japan developed strict guidelines in 2019, which envision the constant control of genetic instability and deep testing of the safety of cells.<\/p>\n

In this process, clinical supervision is especially important. For example, during one of the studies of the treatment of the cornea of the eye, scientists discovered a genetic change in the cells, although one-year observation showed that this was not followed by the development of a tumor. This case confirms once again how critical constant genomic monitoring is for the patient’s safety.<\/p>\n

At the same time, the complexity of production and high self-cost remain a serious challenge. Precisely because of these factors, most of the studies are small-scale. To fill this deficit, Japan actively uses \u201creal-world data\u201d (RWD) and external control groups, which gives scientists the opportunity to draw accurate conclusions even in conditions of small data.<\/p>\n

This experience of Japan clearly shows that the close synergy of the state, scientific circles, and the private sector creates an environment where difficult technologies turn into therapy accessible for the patient. This model today already forms a standard oriented on a global scale, which gives hope that Japanese innovations will have an influence on the healthcare systems of the whole world in the nearest future.<\/p>\n

Source: <\/span>ScienceDirect<\/span><\/a>; <\/span>NHK World<\/span><\/a><\/p>\n



<\/p>\n","protected":false},"excerpt":{"rendered":"

Regenerative medicine is based on the use of those biological mechanisms that allow the organism to regrow and restore damaged tissues. For decades, this field primarily existed in laboratory experiments and theoretical research, although by 2026, technology has reached the stage where its practical use is already a reality. In this turning process, Japan plays […]<\/p>\n","protected":false},"author":5,"featured_media":14050,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594],"tags":[4568,4574,2748],"class_list":["post-14048","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","tag-ips","tag-japan","tag-regenerative-medicine"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/14048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=14048"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/14048\/revisions"}],"predecessor-version":[{"id":14057,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/14048\/revisions\/14057"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/14050"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=14048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=14048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=14048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}